魏尚世 - (螃蟹收藏、玉石、股票投資、旅遊、美食、電影、手足球、作品...)

Medigen to publish COVID-19 research on U.S. journal 02/02/2024 09:53 PM https://focustaiwan.tw/sci-tech/202402020014 A COVID-19 vaccine from Taiwan-based Medigen Vaccine Biologics Corp. CNA file photo Taipei, Feb. 2 (CNA) Research conducted by Taiwan's Centers for Disease Control (CDC) showing the locally-produced Medigen COVID-19 vaccine to be as effective as those from Moderna and Pfizer BioNTech is set to be published in a U.S. medical journal. The research paper will be published in the March issue of Emerging Infectious Diseases, a monthly peer-reviewed journal from the U.S. Centers for Disease Control and Prevention, CDC Deputy Director-General Lo Yi-chun (羅一鈞) told CNA on Friday. Lo said that the CDC would be publishing the positive results of its research into Medigen Vaccine Biologics Corp.'s protein subunit COVID-19 vaccine, which has been proven to provide 90 percent protection against moderate to severe infections in individuals with three doses. The protein subunit vaccine is effective against the Omicron subvariant and could protect those receiving immunization from moderate to severe symptoms and even death, according to Lo. Moreover, the CDC's research is the first large-data set comparison between the strengths of mRNA and protein subunit vaccines, Lo said. Taiwan's CDC explained that data for the research was collected domestically in Taiwan through the nation's vaccine rollout programs. The data used for the comparison was based on more than 60 million vaccine jabs received by over 23 million individuals during the mass Omicron community infections that broke out domestically in 2022. The CDC said the research concluded that the protection provided by Medigen's protein subunit vaccine was equal to that offered by those produced by Moderna and Pfizer BioNTech, which have been proven to be more efficient and long-lasting than those from AstraZeneca (AZ). The research completely maps out the strength of various vaccine combinations between different age groups and the results are available to experts around the world, the CDC said. Lo told CNA that the CDC's findings, which have already been made public, were presented at the 30th Conference on Retroviruses and Opportunistic Infections in Seattle last February. The CDC also advised anyone who received an AZ vaccine as their first two initial inoculation jabs to get additional boosters with next-generation serums. (By Tseng Yi-ning and James Lo) Enditem/cs/ASG

Sat, Feb 03, 2024 page1 Study says Medigen jab as effective as others COVID-19 VACCINE: The study vindicated the Medigen vaccine, which was unfairly criticized in Taiwan, Premier Chen Chien-jen said yesterday By Wu Liang-yi, Lin Chin-hua and Jonathan Chin / Staff reporters, with staff writer Taiwan’s indigenously developed Medigen COVID-19 vaccine is as effective in preventing deaths and serious symptoms as mRNA shots, a study to be published in the US Centers for Disease Control and Prevention’s journal next month showed. An early release of the study is available on the Web site of the Emerging Infectious Diseases journal. The study, conducted by the Centers for Disease and Control (CDC), utilized data from Taiwan’s records of inoculations, hospitalizations and deaths since the local outbreak of the Omicron variant of SARS-CoV-2 in 2022. A syringe of Medigen’s COVID-19 vaccine is pictured in an undated photograph. Photo: Taipei Times CDC Deputy Director-General Philip Lo (羅一鈞) said that the protein subunit-based Medigen vaccine had an effectiveness of 91 percent after three jabs. The mRNA-based BioNTech and Moderna vaccines were 95.8 and 81 percent effective after three jabs respectively, while the viral vector-based AstraZeneca vaccine was 65.7 percent effective, Lo said. The CDC study also found that Medigen and mRNA jabs had a longer efficacy period than the AstraZeneca vaccine, he said. The research is the world’s first big data study on the efficacy of mRNA, protein-subunit and viral-vector COVID-19 vaccines that draw from real-world outcomes, he said, adding that the findings might boost the development of new protein-subunit vaccines, including Novavax. The study vindicates the Medigen vaccine, which was unfairly criticized in the nation, Premier Chen Chien-jen (陳建仁) told an event marking the inking of a strategic alliance between Taiwan Bio-Manufacturing Corp (台灣生物醫藥製造) and US-based National Resilience Inc. Taiwan handled its local outbreak with a conventional strategy, which proved successful in containing the virus’ spread and protecting economic growth, he said, adding that the nation has received international accolades for its accomplishment. The COVID-19 pandemic showed that having pharmaceutical research capability without an industrial base to manufacture medicines at scale would not be enough to meet Taiwan’s needs, National Development Council Minister Kung Ming-hsin (龔明鑫) said. The ability to mass produce medical drugs is crucial to public health as well as national security, but the nation’s NT$1 trillion (US$32.01 billion) biomedical industry has an undersized NT$700 billion to NT$800 billion manufacturing sector, he said. Separately yesterday, Lo said that the CDC had delivered the last 156,000 Novavax XBB doses in its inventory to local governments. The number of available Moderna and Novavax XBB vaccine doses stood at 459.2 million and 315,000 respectively, he said. COVID-19 continues to circulate, with 52 percent of cases now being the JN.1 variant, Lo said, adding that XBB vaccines are about 50 percent effective against mild symptoms in adults. The CDC urged the public to get inoculated ahead of the Lunar New Year holiday, which begins next week. People older than 12 can get either type of the XXB vaccine, while children under that age can only receive Moderna’s version, it said. Information about vaccination locations can be found online at: https://gov.tw/eU4. Additional reporting by CNA https://www.taipeitimes.com/News/front/archives/2024/02/03/2003813011